In this Psychiatric Times Peer Exchange, the panel delves into a comprehensive examination of schizophrenia care, covering the clinical and economic burden of the disease, the multifactorial challenges of treatment adherence, and the evolving landscape of pharmacological options — from first-generation antipsychotics to novel mechanisms of action and alternative delivery systems. The series emphasizes the critical importance of early intervention, patient empowerment, multidisciplinary collaboration, and systemic reform in closing the gap between available evidence and real-world outcomes for patients living with schizophrenia.
-
Dr. Gustavo Alva Contributes to National Research on Tardive Dyskinesia Treatment
Dr. Gustavo Alva recently served as an investigator on KINECT-PRO, a newly published clinical study on tardive dyskinesia (TD), a movement disorder that can develop after long-term use of certain psychiatric medications. It causes involuntary movements, often in the face, mouth, or…
-
Initiating dextromethorphan-bupropion extended release in patients with major depressive disorder: Delphi panel expert consensus recommendations
Clayton, A. H., Alva, G., Bowman, P., Crown, E., Das, B., Doghramji, P., … Miller, J. J. (2026). Initiating dextromethorphan-bupropion extended release in patients with major depressive disorder: Delphi panel expert consensus recommendations. Current Medical Research and Opinion, 42(6), 1243–1256. https://doi.org/10.1080/03007995.2026.2700073 Abstract…
-
Vagus Nerve Stimulation in Difficult-to-Treat Depression: When Does It Work Best?
Author(s)Gustavo Alva, MD, DFAPA Where can vagus nerve stimulation fit into treating depression? View video on YouTube Gus Alva, MD, discussed vagus nerve stimulation (VNS) as an underutilized but clinically important neuromodulation option in the stepwise management of difficult-to-treat depression, from the…